Contact UsInvestorsCareersMediaScienceContact Us
HomePartnershipsWorking With The NHS and other Healthcare OrganisationsCollaborative WorkingCollaborative Working Project between Morriston Hospital, University Hospital of Wales, The Grange University Hospital and Pfizer LimitedCollaborative Working Project between Morriston Hospital, University Hospital of Wales, The Grange University Hospital and Pfizer LimitedDeveloping and coordinating the clinical pathways to review and optimise patients with amyloidosis
Background
The term amyloidosis describes a group of disorders caused by abnormal folding, aggregation and accumulation of certain proteins in the tissues, in an abnormal form known as amyloid deposits. 

Amyloidosis is classified according to the protein that forms the amyloid fibrils, and the clinical picture and symptoms can differ greatly between one amyloid type and another. There are various types of amyloidosis. Different proteins are implicated in different types of amyloids.

The National Amyloidosis Centre (NAC) is currently the only commissioned centre in England which offers a specialised centre of excellence for patients with amyloidosis and is funded via NHS Specialised Commissioning to provide diagnosis and treatment advice for these patients. The increase in patient numbers has meant that the service has outgrown its capacity. In September 2024, NHS England, Highly Specialised Services invited suitably qualified and experienced providers to express interest in delivering services in amyloidosis. In February 2024, the Amyloidosis Networked Model of Care competitive tender outcome established that two hubs will form part of the first wave of the network expansion, thus enabling the extension of expertise across the country and improve access for patients.
Project
This project is aimed at supporting, via a collaborative working agreement between the Morriston Hospital, University Hospital of Wales and The Grange University Hospital and Pfizer UK Ltd., the delivery of a comprehensive plan to educate, improve disease
awareness, develop operational capabilities and deliver patient focused services with equity, all targeted at improving clinical pathways across South Wales.

The project will fund the provision of three Band 7 nurses working one day a week as Amyloidosis Band 7 nurse coordinators to support the care of patients with amyloidosis. This approach aims to ensure that there is a thorough and coordinated clinical pathway to assess amyloidosis patients through local multidisciplinary teams (MDT) and ensure access to diagnostics and licensed treatments in a timely manner.
Benefits
Benefits to patients
  • Improved access to specialised medicines and treatments.
  • Equity of care in South Wales for patients regardless of referral centre and proximity the centre of excellence and hubs.
  • Reduced variation in patient access to specialised medicines across the country and improved equity for amyloidosis patients.
  • Better outcomes for amyloid patients with specialist input from the NAC and the selected hubs.
  • Patient end to end support from referral to treatment and beyond with referring clinicians maintaining patient care. 

Benefits to the NHS
  • Improved pathways that utilise the capacity and specialised clinical competencies for amyloidosis.
  • Efficiency in the functioning of the amyloidosis network.
  • Centralised data collection for regions such as South Wales to demonstrate innovative ways of working that can increase patient care and outcomes.
  • Clinical care aligned with standards of care developed by the NAC for patients in South Wales.
  • Data collection in line with interventions of The Rare Disease Framework and Action Plan for Wales Plan, 2022.

Benefits to Pfizer
  • Understanding resource utilisation for service delivery in amyloidosis.
  • Understanding patient needs in amyloidosis through a feedback process.
  • Establishing an understanding of the needs of amyloidosis patients post-discharge and follow up care.
  • Improved understanding of the network from an MDT perspective.
  • The project will result in the identification of patients who are eligible for appropriate treatments.
  • Expected increase in the speed of uptake of appropriate licensed treatments for eligible patients.
Potential Outcomes
  • Centralised coordination: coordination of patients referred in South Wales to the NAC ensuring equity of access, patient education and expertise regardless of geographical location.
  • Streamlined patient management: Uniform patient follow up by referring clinician, regardless of geographical location of referral, thus ensuring equity and continuity of care.
  • Enhanced communication: Established clinical correspondence pathways between the NAC, hubs and South Wales.
  • Quality assurance and continuous improvement: continuous review of patient pathways, including follow-up and changes implemented in a timely manner.
  • Sufficient data captured to embed into a business case led by the service manager to demonstrate service viability and the respective organisations to submit a business case for NHS to continue investment post the 24-month period.
Proposed Term of the Collaborative Working Project
Planned start date: 1st September 2025.
Planned end date: 1st September 2027.
Resource Allocation
Pfizer Ltd will contribute:
  • Funding:
    • Band 7 nurse coordinator - Morriston Hospital, Swansea Bay University Health Board: £25,288.40
    • Band 7 nurse coordinator - The Grange Hospital, Aneurin Bevan University Health Board: £25,288.40
    • Band 7 nurse coordinator - University Hospital Wales, Cardiff and Vale University Health Board: £25,288.40
  • Human resource: 382.5 hours (£17,212.50 thus £5,737.50 per organisation)
  • Total transfer of value: £93,077.70* (£31,025.90 per organisation)
*This is calculated as the sum of the direct financial contribution by Pfizer PLUS the benefit in kind value of the human resources provided by Pfizer.


Morriston Hospital, University Hospital of Wales and The Grange University Hospital will contribute:
  • Human resource hours: 2907 hours (£130,785.93 thus £43,595.31 per organisation)
ResponsibilityHealthcare Organisation Grants

Pfizer is committed to being transparent about the relationships we have with other organisations. 

PartnershipsDonations and Grants

Find out about the donations and grants we make available to support healthcare, scientific research and education.

PP-TAF-GBR-0008 / August 2025
Science Products Responsibility Partnerships Careers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2025 Pfizer Limited. PP-UNP-GBR-13382  / September 2025. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427.  This website is intended for the general public in the UK.